Researchers from Assembly Biosciences Inc. reported on the preclinical characterization of ABI-5366, a potent helicase-primase inhibitor against both HSV-1 and HSV-2.
Researchers from China Pharmaceutical University and colleagues have provided details on the discovery and preclinical evaluation of [I], a novel stilbene derivative that showed antitumor activity.
Bivictrix Therapeutics plc has released promising final data from a second in vivo efficacy study of its lead clinical candidate BVX-001, a first-in-class Bi-Cygni antibody-drug conjugate (ADC) for the treatment of acute myeloid leukemia (AML).
Sangamo Therapeutics Inc. has signed an evaluation and option agreement with Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly & Co., through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.
Scribe Therapeutics Inc. has announced an expanded collaboration with Sanofi SA, under which Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including for sickle cell disease.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have developed nitrogenous heterocyclic compounds described as as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors.
Recent studies suggest that neutrophils are not only involved in the innate immune response but also may play extended roles in chronic inflammatory disorders and adaptive immune responses as well.
RSS
